Tafamidis use in amyloid cardiomyopathy

Last month, the research round-up provided you with an overview of a range of prescribing practices around antibiotics. This month, we look at three articles for a drug newly recommended to UK prescribers for amyloid cardiomyopathy. The first is a German study of real-world treatment patterns. The second article examines tafamidis efficacy in octogenarians with amyloid cardiomyopathy. In our final article, we will focus on temporal outcomes of patients with amyloid cardiomyopathy.

This study, published in the journal Cardiology and Therapy, sought to determine real-world prescribing patterns of tafamidis with respect to patient characteristics and persistency. Using a non-interventional, retrospective, observational cohort study methodology, the researchers accessed data from the German IQVIA LRx database. This database contains anonymised data around patient-level prescriptions for those with statutory health insurance. After extraction of data on patients aged over 18 who had received at least one prescription for tafamidis 61mg between March 2020 and August 2022, 1565 patients were identified. Baseline characteristics of those included showed that the mean age was 78.3 years and 82.4% were male. This is in line with the disease characteristics of amyloid cardiomyopathy, which was the indication of interest to the researchers.